Vertex to Seek US Approval After Promising Late-Stage Results for Kidney Drug

Vertex passes key test in quest to treat kidney diseases

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.

Vertex says its drug successfully reduced marker of kidney disease in late-stage trial

The biotech company is in a three-way race with Otsuka and Vera Therapeutics to treat the condition, called IgA nephropathy.

Vertex kidney disease drug hits mark in late-stage study

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as having “best-in-class potential” in a competitive field.

Vertex to seek US approval after promising late-stage results for kidney drug

Vertex to seek approval of IgAN drug after Phase III success

Vertex said it will use a priority review voucher to expedite the FDA approval of povetacicept in immunoglobulin A nephropathy (IgAN).The post Vertex to seek approval of IgAN drug after Phase III success appeared first on Clinical Trials Arena.

How did Vertex's drug affect IgA nephropathy markers?

Late stage trial showed a substantial biochemical response Vertex reported that a drug acquired as part of a $4.9 billion deal cut a key disease marker for IgA nephropathy by about half in a late stage clinical trial. The company described this as a meaningful reduction in a marker that clinicians…